Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy

A technology of immunosuppression and gene editing, applied in the direction of immunoglobulin, chemical instruments and methods, biochemical equipment and methods, etc., can solve problems such as deletion, insertion and excision of DNA fragments

Inactive Publication Date: 2018-08-31
EXCISION BIOTHERAPEUTICS INC +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cutting, usually blunt-ended double-stranded cutting, may cause deletions, insertions, and excisions of DNA fragments resulting from defective DNA repair

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
  • Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
  • Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0039] The gRNAs in Example 1 are those disclosed by Wollebo et al. (2015), but it should be understood that the present invention is not limited to those gRNAs. The gRNA includes a gRNA spacer sequence complementary to the JCV T-antigen sequence in the TM1, TM2 or TM3 region. The target sequence can extend from about 20 to 40 or more nucleotides (nt) in length. It should be understood that in different JCV strains or mutant variants, sequences homologous to TM1, TM2 and TM3 can be easily identified by well-known sequencing and genomic techniques.

[0040] An exemplary target sequence in TM1 includes SEQ ID NO: 1 or its complementary sequence SEQ ID NO: 2 on the antiparallel chain. The target sequence can include the PAM sequence in each chain (in figure 1 (Shown in bold and lowercase letters), so that the target sequence may include SEQ ID NO: 3 or its complementary sequence SEQ ID NO: 4 on the antiparallel strand. Therefore, the gRNA complementary to TM1 designated as gRNAm1 ...

example 2

[0109] Example 2: CRISPR / Cpf1 composition and method for elimination of JCV as a co-therapeutic treatment with natalizumab.

[0110] Based on the 3'neighbor of the 5'TTN sequence in the JCV T-Ag genome, the hypothetical target sequence of Cpf1 is disclosed in Table 2 (as the target sequence cm1-cm236). The gene editing composition of the present invention includes at least one gRNA complementary to one of the listed target sequences. The gRNA of the present invention may or may not include a sequence complementary to the PAM sequence of the target sequence, which is listed in brackets at the 5'end of each target sequence in Table 2. The gRNA may be complementary to truncated variants of the listed sequence, for example, a sequence that has been truncated by 1, 2, 3, or more nucleotides at the 3'end. The gRNA may be less than 100% complementary to the target sequence listed in Table 2. For example, gRNA can be 95% complementary to the listed target sequence. The gRNA sequence m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, or at least one argonaute protein, which target at least one nucleotide sequence of the JCV genome.

Description

Technical field [0001] The present invention relates to methods and compositions for the elimination of John Cunningham virus (JCV) from host cells before and during the administration of immunosuppressive therapy to eliminate the activation of latent JCV and subsequent progressive multifocality The risk of leukoencephalopathy (PML). Specifically, the present invention relates to cleavage of target sites within the JCV genome by administering a composition comprising a clustered regularly spaced short palindrome repeat (CRISPR)-related endonuclease and one or more specific guide RNA sequences. Strategy to eliminate JCV. The present invention also relates to strategies that include the administration of JCV targeting compositions including zinc finger nuclease (ZFN) or transcription activator-like effector nuclease (TALEN). Background technique [0002] Therapies have been developed to treat a variety of previously intractable diseases or conditions, such as multiple sclerosis; ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H21/04C12N9/22C12N15/63C12N15/113A61K38/16A61K38/46A61P31/18G01N33/50
CPCC12Q1/70C12N15/102A61P31/20A61K38/465Y02A50/30C12N2740/15041C12N15/00C12N2799/00C12N2310/20A61K39/39541A61K2039/505C07K16/2839C12N15/11A61K48/00
Inventor K·哈利利托马斯·马尔科姆肯尼斯·I·科恩
Owner EXCISION BIOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com